Search
Jun 3, 2024
Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T
Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the...
Sep 6, 2023
Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allo CAR-T as the company plans to discuss a pivotal with FDA.
Jan 10, 2023
Rachel Haurwitz on allo CAR-T at #JPM23
Caribou Biosciences's CEO Rachel Haurwitz talks about her company's allogeneic CD19 CAR-T program that has a PD-1 knockout.
.png){kind=logo}
